Clovis’ PARP drug gets new US ovarian cancer use
Rucaparib gets FDA OK in maintenance use
X
Clovis’ PARP drug gets new US ovarian cancer use
https://pharmaphorum.com/news/clovis-parp-drug-gets-new-us-ovarian-cancer-use/
ovarian cancer
Clovis’ Rubraca close to EU approval in ovarian cancer
CHMP backs conditional approval for PARP drug
AZ’s Lynparza becomes first PARP drug approved in breast cancer
Lynparza first in class approved in breast cancer
Clovis PARP drug gets fast US review in new ovarian cancer use
Impressed by survival data, FDA hastens review in expanded patient group
Tesaro gets European approval on Zejula, set to challenge AZ
Tesaro’s PARP drug approved in wider ovarian cancer population
MicroRNA diagnostic could be big advance in ovarian cancer
AI blood test achieves very high accuracy and specificity for detecting ovarian cancer.
Tesaro’s Zejula primed for EU approval, battle with AZ
EU regulators recommend PARP inhibitor Zejula
Rubraca outshines rivals in ovarian cancer maintenance therapy
Clovis’ Rubraca, the drug showing significant benefits for all ovarian cancer patients in a maintenance setting – and better results than its rivals.
